Denmark to deploy ‘saildrones' in Baltic to protect undersea cables from Russian threat
The arrival of Saildrone, a California-based company, has prompted criticism in Denmark over forging tighter bonds with the US in such a sensitive area as digital security.
The backlash comes amid rapidly changing alliances, evolving technology and ongoing tensions between Copenhagen and Washington after Donald Trump threatened to take over Greenland, which is part of the Danish kingdom.
The 10-metre unmanned vessels, known as 'saildrones', resemble sailing boats but are designed solely to collect data. Using onboard AI, saildrones compile data using multiple sensors, cameras and radar to produce a more detailed picture of maritime activity than satellites can provide.
The company has previously worked with the US navy, which used its vessels to support counter-drug trafficking and illegal fishing operations. Its arrival in Denmark marks the first time it has been used for defence purposes in European waters.
'The purpose of Saildrone is to give eyes and ears where we previously didn't have eyes and ears,' said Richard Jenkins, CEO of Saildrone.
As concerns grow over Russia's so-called shadow fleet – ageing tankers used to circumvent sanctions by transporting crude oil to China and India – saildrones can be used to verify vessel identification and flag unusual movements that may point to undersea sabotage of pipelines or data cables.
'What we're seeing now is commercial shipping fleets being used in military applications,' said Jenkins.
'So whether it's the shadow fleet for Russia trafficking illegal supplies that is getting around sanctions or whether they are trying to do nefarious things like damage infrastructure, we need to be able to track that.'
The Danish armed forces are deploying four saildrones in the Baltic for operational testing to improve its capacity for maritime surveillance and intelligence gathering.
However, the partnership has raised concerns among Denmark's tech leaders.
The software engineer and entrepreneur, David Heinemeier Hansson, told Danish broadcaster DR: 'The problem with American companies is that they have to follow American law, American decrees and the American president. He can demand data at any time, and he can close an account at any time.'
Jacob Herbst, head of the Danish Cybersecurity Council, said: 'With the international situation we are currently seeing, you obviously have to think very carefully when choosing American suppliers in this area.'
Jenkins said they are not getting classified data in Denmark and that data is fully encrypted.
The floating drones can be powered by diesel, wind and solar and can remain at sea for over a year but their average deployment is 100 days. Between 10 and 20 saildrones would be needed to cover the whole of the Baltic.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
39 minutes ago
- Reuters
The race to launch first weight-loss pill
August 19 - Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's (LLY.N), opens new tab Zepbound and Novo Nordisk's ( opens new tab Wegovy. The GLP-1 drugs sold by both companies are weekly injections, although several drugmakers are racing to develop an oral medicine or pill that might prove to be as effective as the injectables. Pills are easier to manufacture and could also avoid some of the supply issues that were initially seen with Novo and Lilly's drugs. Here are some companies developing oral obesity drugs in the hopes of making their mark in a lucrative market: Orforglipron, the company's once-daily oral non-peptide GLP-1 agonist, helped patients shed 12.4% of body weight over 72 weeks at the highest dose in a late-stage trial. Lilly plans to file for regulatory approval by the end of 2025 and is preparing for global submissions and manufacturing scale-up. Oral semaglutide, a pill version of the company's injectable GLP-1 active ingredient, demonstrated about 15% weight loss in a late-stage trial. The drug is currently under regulatory review, with a U.S. FDA decision expected in late 2025. Novo is also exploring next-generation oral combinations. Structure Therapeutics is developing GSBR-1290, a non-peptide oral GLP-1 agonist. Last year, the drug helped reduce weight by 6.2% on average at the end of 12 weeks in a mid-stage study. It is expected to report results from another mid-stage trial in the fourth quarter. The company, in partnership with Hansoh Pharma, is preparing to test HS-10535, an oral small-molecule GLP-1 agonist, in early-stage trials. The drug is currently being tested in lab studies. AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a promising weight-loss signal and a favorable safety profile, with mid stage trials planned under AstraZeneca's lead. Roche, following its acquisition of Carmot Therapeutics, is working on CT-966, an oral GLP-1 agonist. CT-966 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in an early-stage trial last year. The company is developing an oral formulation of VK2735, which targets both GLP-1 and GIP hormones that regulate the body's metabolism. In a mid-stage study of 280 overweight adults with at least one obesity-related comorbidity, the pill achieved up to 12.2% mean weight loss over 13 weeks, compared with placebo. Pfizer was developing danuglipron, initially as a twice-daily oral GLP-1 agonist, but scrapped development after data from a mid-stage trial showed poor tolerability. A once-daily extended-release version was later tested in about 1,400 patients but liver safety concerns remained, dampening the company's plans to enter the obesity drug market.
Telegraph
7 hours ago
- Telegraph
Labour review could put state pension age on course to hit 70
Labour is paving the way for the state pension age to be raised to 70 as a review considers tying future increases to life expectancy. Suzy Morrissey, who has been commissioned by Liz Kendall, the Work and Pensions Secretary, to review the official retirement age, said she would examine the 'merits' of automatic increases to help bolster the public finances. The New Zealander said she would examine the experience of other countries that already automatically link payments to life expectancy, including Denmark, which recently raised its retirement age to 70. Experts warned that automatic increases could create 'chaos' in retirement plans. Ms Morrissey's call for evidence, published by the Department of Work and Pensions (DWP) on Monday, said analysis of 'automatic adjustment mechanisms' used in countries such as Finland, Italy, the Netherlands and Denmark would form a key part of the review. Ms Morrissey noted that UK life expectancy at age 66 had continued to rise, although she conceded that improvements had been much slower than forecast a decade ago amid a reversal during lockdown. The state pension age will start to rise to 67 from next year and is currently scheduled to rise again to 68 between 2044 and 2046. Any planned increases beyond this are likely to be at least another decade away. However, politicians have previously tried to bring forward increases amid concerns about the burden placed on public finances by the triple lock, which guarantees that the state pension rises by at least 2.5pc each year. Jeremy Hunt, the former chancellor, attempted to bring the increase to 68 forward to the late 2030s. However, he was forced to shelve the plans following a decline in life expectancy that left ministers struggling to justify the change. A man aged 66 in 2050 is now projected to live until 87, compared with 90 using 2014-based projections. Ms Morrissey said she would make her recommendations, which are expected in several years, 'in light of the long-term demographic pressures the country faces', as she noted that spending on the state pension had increased by 19pc over the past decade and 70pc over the past 20 years in real terms. Denmark has tied the official retirement age to life expectancy since 2006 and is one of nine OECD countries to do so. The Danish approach effectively caps the amount of time someone can spend claiming state support, legislating that an average of 14.5 years should be spent in retirement. This means that the retirement age rises by one year for every year life expectancy increases in Denmark. By contrast, the UK Government has set out a principle that future generations should spend 'up to a third' of their adult life in retirement. In 2017, the Government Actuary's Department (GAD) suggested the state pension age would rise to 70 in the 2050s if people spend 32pc of their adult life in retirement, though the GAD will consider changes to life expectancy when it updates its projections for this review. Sir Steve Webb, a former pensions minister, noted that automatically linking life expectancy to the state pension age may have seen it swing by up to eight years, depending on whether you used 2012 or 2014 population projections. He said: 'Having a completely automatic formula to move from changes in life expectancy to changes in state pension age could cause chaos for people's financial planning. 'Every time the population projections are updated, this could move the dates for pension age changes by up to a decade, which would make it impossible for people to plan for their retirement finances. 'Having a rigid rule for setting pension ages creates more volatility and uncertainty than an approach which is more based on judgment and taking into account a wider range of factors.' Catherine Foot, director of the Standard Life Centre for the Future of Retirement, added that any increases would have to be accompanied by policies that helped people to stay in work. The Government has admitted that the previous increase in the state pension age to 66 in the 2010s left 89,000 would-be pensioners languishing on sickness benefits because they were too ill to work. Ms Foot said: 'Working until even the current state pension age is not easy for everyone. The group experiencing the fastest-growing rate of poverty for any working-age adult age group is people aged 60-65, many of whom have fallen out of work due to things like ill health, caring responsibilities or ageism in the labour market. 'Using average life expectancy as the yardstick with which to determine the state pension age inevitably increases inequality and poverty among the pre-retirement population, since it moves the state pension age further away for people who have fallen out of work and are struggling to get back in.'
Reuters
21 hours ago
- Reuters
Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers
Aug 18 (Reuters) - Novo Nordisk ( opens new tab said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms. U.S.-listed shares of the Danish drugmaker were up 5.3%, while shares of GoodRx rose 34.2%. Novo and rival Eli Lilly (LLY.N), opens new tab have expanded into direct-to-consumer sales for the highly effective and sought-after medicines, in part due to competition from online telehealth companies and pharmacies that sell cheaper compounded versions. Novo already sells Wegovy, the weight-loss version of Ozempic, through its NovoCare pharmacy for $499. The latest offer is aimed at patients who do not have insurance coverage. Its shares were also trading higher after Wegovy secured U.S. FDA approval for the liver disease metabolic dysfunction-associated steatohepatitis, or MASH, on Friday. GoodRx (GDRX.O), opens new tab will sell Wegovy and Ozempic at $499 monthly to eligible self-paying patients. A spokesperson for Novo said it expected Ozempic cash sales to account for about 10% of total prescriptions - the same level of market penetration the company has experienced with Wegovy. Novo said earlier this month it expects continued competition from copycat versions and rising pressure from Lilly. List prices for each drug in the United States are about $1,000 per month or more, but insured patients pay far less. Eli Lilly offers single-dose vials of its weight-loss drug Zepbound on its website, LillyDirect, for $499 per month or less, regardless of insurance status. Lilly does not sell its diabetes drug Mounjaro on LillyDirect. Novo said the new offer for Ozempic was part of ongoing efforts to explore new collaborations and approaches towards improving access to authentic semaglutide medicines. In April, it said it was working with telehealth firms Ro and LifeMD (LFMD.O), opens new tab to sell Wegovy to expand access to cash-paying patients.
